Dr. Keith Brunt is the main founder & leader of the IMPART team, a national virtual research institute headquartered at Dalhousie Medicine New Brunswick in Saint John, NB. He is an associate professor at Dalhousie Medicine New Brunswick, a translational scientist in the cardiovascular surgery/ cardiology departments of the New Brunswick Heart Centre.
Dr. Brunt is Medical Science Advisor to Protokinetix, Inc. Protokinetix (www.protokinetix.com, OTCQB: PKTX) has developed PKX-001, a revolutionary new peptide with large applications in cell therapy, ophthalmology, dermatology, inflammatory diseases and many others. PKX-001, when applied to cells, completely shuts down cell-level inflammation (the root cause of many diseases) and dramatically increases cell health, lifespan and functionality.
Protokinetix is completing Phase 1 human trials to cure diabetes via PKX-001-treated islet cell transplants, led by Dr. James Shapiro in Edmonton, Canada.